XML 51 R40.htm IDEA: XBRL DOCUMENT
v3.21.2

Collaborative Agreements (Details) |  | 1 Months Ended | 9 Months Ended | 12 Months Ended |  |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Aug. 15, 2017 USD ($) | Dec. 24, 2018 | Sep. 25, 2017 USD ($) | May 26, 2017 USD ($) | Aug. 31, 2016 USD ($) | Aug. 31, 2016 TWD ($) | Jul. 27, 2016 USD ($) | Dec. 31, 2015 USD ($) | Sep. 30, 2021 USD ($) | Dec. 31, 2017 USD ($) | Jun. 29, 2021 shares | Dec. 31, 2020 USD ($) | Nov. 19, 2020 shares | Sep. 30, 2019 USD ($) shares | Aug. 05, 2019 USD ($) shares | Dec. 18, 2018 shares
Collaborative Agreements (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments royalty percentage |  |  |  |  |  |  |  |  | 12.00% |  |  |  |  |  |  |
Additional paid-in capital |  |  |  |  |  |  |  |  | $ 49,716,411 |  |  | $ 40,751,807 |  |  |  |
Co-Dev agreement, description |  | the Company received the remaining balance of $2,550,000 in the form of newly issued shares of Rgene’s Common Stock, at the price of NT$50 (approximately equivalent to $1.60 per share), for an aggregate number of 1,530,000 shares, which accounted for equity method long-term investment as of December 31, 2018. During the year ended December 31, 2018, the Company has recognized investment loss of $549. |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares issued (in Shares) | shares |  |  |  |  |  |  |  |  |  |  | 6,000 |  | 50,000 |  |  | 1,548
BHK Co-Development Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Agreements (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments to BioLite in cash |  |  |  |  |  | $ 31,649,000 | $ 10,000,000 |  |  |  |  |  |  |  |  |
Description of payment settlement |  |  |  |  |  |  | ●Upon the signing of the BHK Co-Development Agreement: $1 million, or 10% of total payment ● Upon the first Investigational New Drug (IND) submission and BioLite Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or 10% of total payment ● At the completion of first phase II clinical trial: $1 million, or 10% of total payment ● At the initiation of phase III of clinical trial research: $3 million, or 30% of total payment ●Upon the New Drug Application (NDA) submission: $4 million, or 40% of total payment |  |  |  |  |  |  |  |  |
Upfront cash payment |  |  |  |  |  |  |  | $ 1,000,000 |  |  |  |  |  |  |  |
Percentage of payments under co-development agreement |  |  |  |  |  |  |  | 10.00% |  |  |  |  |  |  |  |
Common stock newly issued, value |  |  |  |  | $ 1,000,000 |  |  | $ 10,000,000 |  |  |  |  |  |  |  |
Collaborative agreements, description |  |  |  |  |  |  |  | In 2015, the Company recognized the cash receipt in a total of NT$50 million, approximately equivalent to $1.6 million, as collaboration revenue when all research, technical, and development data was delivered to BHK. | In addition to the total of NT$50 million, approximately equivalent to $1.60 million, BioLite Taiwan is entitled to receive 50% of the future net licensing income or net sales profit. As of September 30, 2021 and December 31, 2020, the Company has not earned the royalty under the BHK Collaborative Agreements. |  |  |  |  |  |  |
Co-Dev Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Agreements (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of payments under co-development agreement |  |  |  | 50.00% |  |  |  |  |  |  |  |  |  |  |  |
Company cash payments | $ 3,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Addition cash payment |  |  |  | $ 3,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Additional paid-in capital |  |  |  |  |  |  |  |  |  | $ 3,000,000 |  |  |  |  |  |
Amount received from BriVision |  |  |  |  |  |  |  |  |  | 450,000 |  |  |  |  |  |
Collaborative Arrangement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Agreements (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of payments under co-development agreement |  |  |  |  |  |  |  |  | 50.00% |  |  |  |  |  |  |
Common stock newly issued, value |  |  |  |  |  |  |  |  | $ 3,000,000 |  |  |  |  |  |  |
Company cash payments |  |  |  |  |  |  |  |  | $ 3,000,000 |  |  |  |  |  |  |
Licensing rights |  |  | $ 3,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development expense |  |  |  |  |  |  |  |  |  | $ 3,000,000 |  |  |  |  |  |
BioFirst Stock Purchase Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Agreements (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amount received from BriVision |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 3,000,000 | $ 2,902,911 |
Shares issued (in Shares) | shares |  |  |  |  |  |  |  |  |  |  |  |  |  | 428,571 | 414,702 |

X
- References No definition available. + Details
Name: | abvc_AdditionCashPayment
Namespace Prefix: | abvc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Co-Dev agreement description. + References No definition available. + Details
Name: | abvc_CoDevAgreementDescription
Namespace Prefix: | abvc_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Agreements, description + References No definition available. + Details
Name: | abvc_CollaborativeAgreementsDescription
Namespace Prefix: | abvc_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | abvc_CollaborativeAgreementsDetailsLineItems
Namespace Prefix: | abvc_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | abvc_IssuanceOfStockValue
Namespace Prefix: | abvc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Milestone payments. + References No definition available. + Details
Name: | abvc_MilestonePayments
Namespace Prefix: | abvc_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone payments royalty percentage. + References No definition available. + Details
Name: | abvc_MilestonePaymentsRoyaltyPercentage
Namespace Prefix: | abvc_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of payments under co-development agreement. + References No definition available. + Details
Name: | abvc_PercentageOfPaymentsUnderCodevelopmentAgreement
Namespace Prefix: | abvc_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of upfront payments which are paid during the term of agreement. + References No definition available. + Details
Name: | abvc_UpfrontCashPayment
Namespace Prefix: | abvc_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 852 -SubTopic 10 -Section 55 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 65 -Paragraph 15 -Subparagraph (g)(2) -URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_AdditionalPaidInCapital
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(a),(d)) -URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227 + Details
Name: | us-gaap_CostOfGoodsAndServicesSold
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount payable to related parties classified as other. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(k)(1)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.15(3),(4)) -URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.17) -URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 + Details
Name: | us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of other research and development expense. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_OtherResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Cash payments related to participation costs. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 926 -SubTopic 230 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6473203&loc=d3e55336-107963 + Details
Name: | us-gaap_PaymentsForParticipationLiabilities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Description of the terms and manner of settlement of the related party transaction. + References No definition available. + Details
Name: | us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644 + Details
Name: | us-gaap_SharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=abvc_BHKCoDevelopmentAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=abvc_CodevelopmentagreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=abvc_BioFirstStockPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |